These Were the 3 Top-Performing Stocks in the Nasdaq-100 in August 2025

In August 2025, while the Nasdaq-100 index posted a modest 0.9% gain, three companies significantly outperformed. Intel led with a 23% surge, attributed to a unique U.S. government financing deal involving the acquisition of 9.9% of its stock. AppLovin followed with a 22.5% increase, driven by strong Q2 earnings that saw revenue jump 77% year-over-year and unadjusted net profits rise 164%. Idexx Laboratories also posted a 21.1% gain, fueled by robust Q2 growth in its pet-care products and services.

Analysis

While the Nasdaq-100 index remained nearly flat with a 0.9% gain in August 2025, a few constituents delivered significant outperformance driven by distinct, company-specific catalysts. Intel (INTC) led with a 23% stock increase, primarily fueled by a unique financing deal where the U.S. government acquired a 9.9% stake. However, the long-term benefit of this arrangement is ambiguous, with potential shareholder dilution weighing against the capital infusion, and the stock remains 10% below its 2025 highs. In contrast, AppLovin's (APP) 22.5% surge was fundamentally driven by an exceptional second-quarter earnings report, which featured a 77% year-over-year revenue jump and a 164% increase in unadjusted net profits, indicating high-quality earnings that have propelled the stock to new all-time highs. Similarly, Idexx Laboratories (IDXX) rose 21.1% following a strong beat-and-raise Q2 performance, with robust growth in its consumable pet-care products, recurring service revenues, and the successful North American launch of a new canine cancer test. This performance suggests Idexx will continue to command a premium valuation as a healthy growth investment.

Key Decisions for Investors

• AppLovin's fundamental strength, evidenced by 77% revenue growth and a 164% rise in unadjusted net profits, suggests its rally is well-supported by operational excellence, although its new all-time highs may warrant careful entry point consideration.
• The catalyst for Intel's 23% gain is a non-operational government financing deal, creating uncertainty around potential shareholder dilution; investors should monitor the specific terms and their impact on fundamentals before attributing this to a core business turnaround.
• Idexx Laboratories' consistent growth from recurring revenues and product innovation justifies its premium valuation, making it a potentially stable holding for growth-oriented investors focused on the resilient pet healthcare market.